Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 340 of 5804
-
Smart scans aim to spare healthy lung during cancer radiation
Symptom relief Not yet recruitingStereotactic body radiotherapy (SBRT) has an increasing role in the treatment of both primary and secondary lung tumors. However, lung SBRT remains associated with significant radiation induced lung injury (RILI). Indeed, the reported incidence of symptomatic radiation induced lu…
Phase: PHASE3 • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New shot may stop hives from cold and scratching
Disease control Recruiting nowThe purpose of this Phase 3, randomized, double-blind, placebo-controlled study is to assess the activity and safety of barzolvolimab compared to placebo in participants with cold induced urticaria or symptomatic dermographism who remain symptomatic despite the use of H1-antihist…
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for kidney cancer: drug combo after radiation shows promise in early trial
Disease control Recruiting nowThe purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients with oligometastatic clear cell renal cell carcinom…
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Recruiting nowA Phase 1a/1b Open-Label Study with Dose Escalation and Expansion Phases to Evaluate Safety and Preliminary Efficacy of Naïve HBI0101 CART Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma.
Phase: PHASE1 • Sponsor: Hadassah Medical Organization • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New mRNA vaccine targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThe main objective of this study is to observe and evaluate the safety and tolerability of the XP-006 personalized tumor mRNA vaccine for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. Secondary objectives focus on evaluating preliminary efficacy through s…
Phase: PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Promising drug duo targets Hard-to-Treat HER2 cancers
Disease control Not yet recruitingThis study is a prospective, multi-cohort clinical trial designed to evaluate the preliminary efficacy and safety of zanidatamab in combination with tislelizumab and chemotherapy/radiotherapy for patients with HER2-positive locally advanced or metastatic gastrointestinal tumors.
Phase: PHASE2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could steroids save lives in severe parrot fever pneumonia?
Disease control Not yet recruitingSevere community-acquired pneumonia caused by psittacosis is a form of atypical-pathogen community-acquired pneumonia that often requires critical care management. It can occur in immunocompetent adults, has an abrupt onset and rapid progression, and may quickly deteriorate to pr…
Phase: PHASE3 • Sponsor: Qingyuan Zhan • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New heart valve repair device could help High-Risk patients avoid surgery
Disease control Not yet recruitingTo confirm the effectiveness and safety of the DragonFly M2 Transcatheter Mitral Valve Repair System for the treatment of symptomatic moderate-to-severe (3+) or severe (4+) degenerative mitral regurgitation in high surgical risk subjects.The safety and effectiveness of the first-…
Phase: NA • Sponsor: Hangzhou Valgen Medtech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Triple-Target CAR t cells take on tough blood cancers
Disease control TerminatedThis phase I trial tests the safety, side effects and best dose of anti-CD19/20/22 chimeric antigen receptor (CAR) T cells (TriCAR19.20.22 T cells) and how well they work in treating patients with non-Hodgkin lymphoma, acute lymphoblastic leukemia (ALL) and chronic lymphocytic le…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New fibromyalgia drug AXS-14 enters final testing phase
Symptom relief Recruiting nowThe study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
Phase: PHASE3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Could a statin help save babies from early delivery?
Disease control Recruiting nowIn pregnancies with placental insufficiency, the only available treatment is close monitoring to determine the point at which the risks of preterm birth for the baby are lower than the risks of continuing the pregnancy. Therefore, safely prolonging pregnancy is the current manage…
Phase: PHASE2 • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Cell therapy Descartes-08 tested in teens with lupus and other autoimmune diseases
Disease control Recruiting nowSafety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
Phase: PHASE1, PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New antibody shows promise against Post-Transplant virus threat
Disease control Not yet recruitingEBV DNAemia is defined as the presence of EBV-DNA load in peripheral blood exceeding the normal threshold, serving as a key diagnostic indicator for EBV-associated post-transplant lymphoproliferative disorder (EBV-PTLD). According to the European Conference on Infections in Leuke…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug combo aims to stop liver cancer recurrence after surgery
Disease control Recruiting nowSurgical resection is the preferred therapeutic modality for patients with resectable hepatocellular carcinoma (HCC). However, the recurrence rate of HCC remains up to 70%. Neoadjuvant therapy for HCC could potentially reduce the risk of postoperative recurrence and prolong overa…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug targets Fuel-Hungry lung cancer cells in phase 2 trial
Disease control Recruiting nowThis is a Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer following standard of care treatment with chemotherapy and immunotherapy.
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
MS patients may soon swap IV drips for quick shots
Disease control Recruiting nowThis is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New study: which first treatment works best for severe aplastic anemia?
Disease control Not yet recruitingThis study aims to compare the efficacy and safety of HLA-haploidentical hematopoietic stem cell transplantation (HLA-haplo HSCT) versus optimal immunosuppressive therapy (IST) as first-line treatments for severe aplastic anemia (SAA) through a real-world cohort design. The selec…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cholera vaccine trial aims to protect families in High-Risk areas
⭐️ VACCINE ⭐️ Recruiting nowThis phase II study is intended to determine the immunogenicity and safety of single dose and two doses of OSP:rTTHc cholera conjugate vaccine (CCV) with or without alum adjuvant. The study will guide the future dosing schedule and formulation of CCV (with or without Aluminum pho…
Phase: PHASE2 • Sponsor: International Vaccine Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:03 UTC
-
First gene therapy trial launches for rare childhood disease MLIV
Disease control ENROLLING_BY_INVITATIONSafety and Efficacy of AAV9.hMCOLN1co for patients with Mucolipidosis Type IV(MLIV): A Single-Center, Interventional, Open-Label, Single-Arm Clinical Study. The goal of this clinical trial is to evaluate whether a gene therapy can safely treat children with MLIV.
Phase: PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy aims to shrink prostate cancer tumors
Disease control Recruiting nowThe purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC